News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘ChildhoodCancer’ clear

  • Scott A. Armstrong, MD, PhD, an internationally renowned pediatric hematologist/oncologist, has been named Chair of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, and the David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School. He will also serve as Associate Chief of the Division of Hematology and Oncology at Boston Children’s Hospital.

Tags: Appointments, ChildhoodCancer

  • Children with acute lymphoblastic leukemia (ALL) who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, despite having received the same treatment. The findings are significant because ALL that relapses early is more difficult to successfully treat.

Tags: ChildhoodCancer, Disparities, Leukemia

  • Researchers found a way of differentiating angiocentric gliomas from other low-grade pediatric brain tumors and developed a pathological test that will help children avoid unnecessary and potentially damaging additional therapies.

Tags: BasicResearch, ChildhoodCancer, BrainTumors

  • Clinical genomic sequencing is feasible in pediatric oncology and can be used to recommend therapy or pinpoint diagnosis in children with solid tumors according to research led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center. The findings, published in JAMA Oncology, represent a significant step in making precision medicine available to children with cancer.

Tags: ChildhoodCancer, TargetedTherapy, Genetics

  • Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center. While the overall cure rate for ALL is high, about one to two percent of children die during the first month of therapy from treatment complications, primarily infection-related.

Tags: ChildhoodCancer, Leukemia

  • Turning off a single gene leads to a roughly three-to-five-fold gain in the yield of laboratory methods for producing red blood cells from stem cells, according to new research published in Cell Stem Cell. The findings suggest a way to cost-effectively manufacture red blood cells from stem cells; the patients who could potentially benefit include those who cannot use blood currently available in blood banks.

Tags: BasicResearch, ChildhoodCancer, Genomics

  • Disparities in outcomes for children with retinoblastoma — a rare eye tumor usually discovered in routine pediatric check-ups — suggest unequal access to primary care, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report in a study published in the journal JAMA Pediatrics. Although virtually all the children in the study survived, Hispanic children and children who lived in disadvantaged areas were more likely to lose an eye due to late diagnosis.

Tags: ChildhoodCancer, ChildhoodCancerSurvivorship, Disparities

  • Almost one-third of families whose children were being treated for cancer faced food, housing or energy insecurity and one-quarter lost more than 40 percent of household income, according to a new study from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center published in Pediatric Blood & Cancer.

Tags: ChildhoodCancer, CopingWithCancer

  • New findings led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center show informing parents about their child's cancer prognosis – even when the prognosis is less than favorable – is much more likely to give parents peace of mind and hope rather than increase their anxiety or cause them to become depressed.

Tags: ChildhoodCancer

  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a Memorial Sloan Kettering clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia. Dana-Farber/Boston Children’s is the only site in New England to offer this breakthrough experimental approach that triggers a patient's immune system to attack cancer cells.

Tags: ChildhoodCancer, Immunotherapy

Showing 1-10 of 51 items